Table of Content

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Investment In R&D
4.2.2 Increase In Research Academies And Industry Collaborations
4.2.3 Rise In Proteomics And Genomics Research
4.3 Market Restraints
4.3.1 High Cost Of Research Antibodies
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Monoclonal Antibodies
5.1.2 Polyclonal Antibodies
5.2 By Source
5.2.1 Rabbit
5.2.2 Mouse
5.2.3 Goat
5.2.4 Others
5.3 By Product
5.3.1 Primary
5.3.2 Secondary
5.4 By Application
5.4.1 Immunology
5.4.2 Infectious Diseases
5.4.3 Stem Cells
5.4.4 Oncology
5.4.5 Others
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bio-Rad Laboratories, Inc.
6.1.2 Abcam plc.
6.1.3 Merck KGaA
6.1.4 Thermo Fisher Scientific
6.1.5 Becton, Dickinson and Company
6.1.6 F. Hoffmann-La Roche Ltd
6.1.7 Lonza
6.1.8 PerkinElmer Inc.
6.1.9 Cell Signaling Technology, Inc
6.1.10 Agilent Technologies


7 MARKET OPPORTUNITIES AND FUTURE TRENDS